Skip to main content

Table 2 Survival (Life Table)

From: Mortality in patients treated with intravitreal bevacizumab for age-related macular degeneration

Beva-cizumab Year Entering Interval Withdrawing during Interval Exposed to Risk Terminal Events Proportion Terminating Cumulative Proportion Surviving at End of Interval
No 0–1 10,756 3050 9231 517 .06 .94
  1–2 7189 2336 6021 327 .05 .89
  2–3 4526 1443 3805 219 .06 .84
  3–4 2864 963 2383 124 .05 .80
  4–5 1777 770 1392 73 .05 .76
  5–6 934 611 629 32 .05 .72
  6–7 291 285 149 6 .04 .69
Yes 0–1 5385 1527 4622 470 .10 .90
  1–2 3388 1099 2839 238 .08 .82
  2–3 2051 631 1736 168 .10 .74
  3–4 1252 407 1049 99 .09 .67
  4–5 746 313 590 63 .11 .60
  5–6 370 249 246 21 .09 .55
  6–7 100 96 52 4 .08 .51